<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">antibiotics-101</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Белок микротрубочек βIII-тубулин: строение, экспрессия и функции в нормальных и опухолевых клетках</article-title><trans-title-group xml:lang="en"><trans-title>Microtubule Protein βIII-Tubulin: Structure, Expression and Functions in Normal and Tumor Cells</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамичев</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamichev</surname><given-names>I. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богуш</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogush</surname><given-names>T. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богуш</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogush</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Терентьева</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Terentyeva</surname><given-names>N. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кирсанов</surname><given-names>В. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kirsanov</surname><given-names>V. Y.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Давыдов</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Davydov</surname><given-names>M. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federaton</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Московский государственный университет им. М. В. Ломоносова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>M. V. Lomonosov Moscow State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Первый московский государственный медицинский университет им. И. М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I. M. Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>06</day><month>05</month><year>2020</year></pub-date><volume>63</volume><issue>7-8</issue><fpage>79</fpage><lpage>90</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; ООО «Издательство ОКИ», 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">ООО «Издательство ОКИ»</copyright-holder><copyright-holder xml:lang="en">ООО «Издательство ОКИ»</copyright-holder><license xlink:href="https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/101">https://www.antibiotics-chemotherapy.ru/jour/article/view/101</self-uri><abstract><p>В обзоре литературы представлены данные о белке микротрубочек βIII-тубулине (TUBB3): его структуре, функциях, роли в опухолевой прогрессии, экспрессии в нормальных клетках, а также в опухолях нервной системы и в эпителиальных опухолях разных локализаций. Рассмотрены основные принципы работы системы микротрубочек и связь TUBB3 с родственными белками семейства ß-тубулинов. Проанализированы перспективы использования TUBB3 в клинической практике как прогностического маркера агрессивности течения заболевания и резистентности опухоли к лекарственной терапии. Сформулировано новое представление о молекулярной диагностике локальной распространённости опухолевого процесса на основании сравнительной оценки уровня экспрессии TUBB3 в нормальной и опухолевой ткани каждого больного. В заключение обоснована необходимость изучения экспрессии TUBB3 и других опухолевый маркеров не только в самой опухоли, но и в нормальной ткани органа, визуально не вовлечённой в опухолевый процесс.</p></abstract><trans-abstract xml:lang="en"><p>The present review contains data on microtubular protein ßIII-tubulin (TUBB3): its structure, functions, role in tumor progression, expression in normal cells and in neural and epithelial tumors of different origins. Basic working principles of microtubular system and links between TUBB3 and related β-tubulins are also briefly reviewed. We analyzed the clinical potential of TUBB3 as prognostic marker of tumor aggressiveness and drug-resistance and suggested that locally disseminated tumor cells might be found by comparison of TUBB3 expression in normal and tumor tissue of each patient. Finally, we conclude that screening for TUBB3 and other tumor markers in morphologically normal tissue adjacent to the tumor is essential for accurate diagnostics.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>микротрубочки</kwd><kwd>цитоскелет</kwd><kwd>опухолевая трансформация</kwd><kwd>метастазирование</kwd><kwd>лекарственная устойчивость</kwd><kwd>прогностические маркеры</kwd><kwd>молекулярная диагностика злокачественных новообразований</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ß-тубулин</kwd><kwd>TUBB3</kwd><kwd>ß-tubulin</kwd><kwd>TUBB3</kwd><kwd>microtubules</kwd><kwd>cytoskeleton</kwd><kwd>neoplastic transformation</kwd><kwd>metastasis</kwd><kwd>drug-resistance</kwd><kwd>prognostic markers</kwd><kwd>molecular diagnosis of malignant tumors</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-265.</mixed-citation><mixed-citation xml:lang="en">Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-265.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">David-Pfeuty T., Erickson H.P., Pantaloni D. Guanosinetriphosphatase activity of tubulin associated with microtubule assembly. Proc Natl Acad Sci USA 1977; 74: 12: 5372-5376.</mixed-citation><mixed-citation xml:lang="en">David-Pfeuty T., Erickson H.P., Pantaloni D. Guanosinetriphosphatase activity of tubulin associated with microtubule assembly. Proc Natl Acad Sci USA 1977; 74: 12: 5372-5376.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rezania V., Azarenko O., Jordan M.A. et al. Microtubule assembly of isotypically purified tubulin and its mixtures. Biophys J 2008; 95: 4: 1993-2008.</mixed-citation><mixed-citation xml:lang="en">Rezania V., Azarenko O., Jordan M.A. et al. Microtubule assembly of isotypically purified tubulin and its mixtures. Biophys J 2008; 95: 4: 1993-2008.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Luduena R.F. Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 1998; 178: 207-275.</mixed-citation><mixed-citation xml:lang="en">Luduena R.F. Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 1998; 178: 207-275.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gadadhar S., Bodakuntla S., Natarajan K. et al. The tubulin code at a glance. J Cell Sci 2017; 130: 8: 1347-1353.</mixed-citation><mixed-citation xml:lang="en">Gadadhar S., Bodakuntla S., Natarajan K. et al. The tubulin code at a glance. J Cell Sci 2017; 130: 8: 1347-1353.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Luduena R.F. A hypothesis on the origin and evolution of tubulin. Int Rev Cell Mol Biol 2013; 302: 41-185.</mixed-citation><mixed-citation xml:lang="en">Luduena R.F. A hypothesis on the origin and evolution of tubulin. Int Rev Cell Mol Biol 2013; 302: 41-185.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ono S. Ancient linkage groups and frozen accidents. Nature. 1973; 244: 5414: 259-262.</mixed-citation><mixed-citation xml:lang="en">Ono S. Ancient linkage groups and frozen accidents. Nature. 1973; 244: 5414: 259-262.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Katsetos C.D., Herman M.M., Mörk S.J. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 2003; 55: 2: 77-96.</mixed-citation><mixed-citation xml:lang="en">Katsetos C.D., Herman M.M., Mörk S.J. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 2003; 55: 2: 77-96.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Panda D., Miller H.P., Banerjee A. et al. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U. S. A. 1994; 91: 24: 11358-11362.</mixed-citation><mixed-citation xml:lang="en">Panda D., Miller H.P., Banerjee A. et al. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U. S. A. 1994; 91: 24: 11358-11362.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang Y.Q., Oblinger M.M. Differential regulation of beta III and other tubulin genes during peripheral and central neuron development. J Cell Sci 1992; 103 ( Pt 3): 643-651.</mixed-citation><mixed-citation xml:lang="en">Jiang Y.Q., Oblinger M.M. Differential regulation of beta III and other tubulin genes during peripheral and central neuron development. J Cell Sci 1992; 103 ( Pt 3): 643-651.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Drâberovâ E., Del Valle L., Gordon J. et al. Class III β-tubulin is constitutively coexpressed with glial fibrillary acidic protein and nestin in midgestational human fetal astrocytes: implications for phenotypic identity. Neuropathol Exp Neurol 2008; 2008: 341-354.</mixed-citation><mixed-citation xml:lang="en">Drâberovâ E., Del Valle L., Gordon J. et al. Class III β-tubulin is constitutively coexpressed with glial fibrillary acidic protein and nestin in midgestational human fetal astrocytes: implications for phenotypic identity. Neuropathol Exp Neurol 2008; 2008: 341-354.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Portyanko A., Kovalev P., Gorgun J., Cherstvoy E. Beta(III)-tubulin at the invasive margin of colorectal cancer: possible link to invasion. Virchows Arch 2009; 454: 5: 541-548.</mixed-citation><mixed-citation xml:lang="en">Portyanko A., Kovalev P., Gorgun J., Cherstvoy E. Beta(III)-tubulin at the invasive margin of colorectal cancer: possible link to invasion. Virchows Arch 2009; 454: 5: 541-548.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Jouhilahti E.M., Peltonen S., Peltonen J. Class III beta-tubulin is a component of the mitotic spindle in multiple cell types. J Histochem Cytochem 2008; 56: 12: 1113-1119.</mixed-citation><mixed-citation xml:lang="en">Jouhilahti E.M., Peltonen S., Peltonen J. Class III beta-tubulin is a component of the mitotic spindle in multiple cell types. J Histochem Cytochem 2008; 56: 12: 1113-1119.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Guo J., Walss-Bass C., Luduena R.F. The beta isotypes of tubulin in neuronal differentiation. Cytoskeleton (Hoboken) 2010; 67: 7: 431-441.</mixed-citation><mixed-citation xml:lang="en">Guo J., Walss-Bass C., Luduena R.F. The beta isotypes of tubulin in neuronal differentiation. Cytoskeleton (Hoboken) 2010; 67: 7: 431-441.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Fanara P. et al. Stabilization of hyperdynamic microtubules is neuroprotective in amyotrophic lateral sclerosis. J Biol Chem 2007; 282: 32: 23465-23472.</mixed-citation><mixed-citation xml:lang="en">Fanara P. et al. Stabilization of hyperdynamic microtubules is neuroprotective in amyotrophic lateral sclerosis. J Biol Chem 2007; 282: 32: 23465-23472.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gan P.P., Pasquier E., Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007; 67: 19: 9356-9363.</mixed-citation><mixed-citation xml:lang="en">Gan P.P., Pasquier E., Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007; 67: 19: 9356-9363.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Davies K.J., Doroshow J.H. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 1986; 261: 7: 3060-3067.</mixed-citation><mixed-citation xml:lang="en">Davies K.J., Doroshow J.H. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 1986; 261: 7: 3060-3067.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sheldon K.L., Maldonado E.N., Lemasters J.J. et al. Phosphorylation of voltage-dependent anion channel by serine/threonine kinases governs its interaction with tubulin. PLoS One / ed. Kahle P J 2011; 6: 10: e25539.</mixed-citation><mixed-citation xml:lang="en">Sheldon K.L., Maldonado E.N., Lemasters J.J. et al. Phosphorylation of voltage-dependent anion channel by serine/threonine kinases governs its interaction with tubulin. PLoS One / ed. Kahle P J 2011; 6: 10: e25539.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Rostovsteva, T.K., Gurnev, P.A., Chen, M.Y., Bezrukov S.M. Membrane lipid composition regulates tubulin interaction with mitochondrial voltage-dependent anion channel. Biol Chem 2012; 287: 29589-29598.</mixed-citation><mixed-citation xml:lang="en">Rostovsteva, T.K., Gurnev, P.A., Chen, M.Y., Bezrukov S.M. Membrane lipid composition regulates tubulin interaction with mitochondrial voltage-dependent anion channel. Biol Chem 2012; 287: 29589-29598.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Cicchillitti L., Penci R., Di Michele M. et al. Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin. Mol Cancer Ther 2008; 7: 7: 2070-2079.</mixed-citation><mixed-citation xml:lang="en">Cicchillitti L., Penci R., Di Michele M. et al. Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin. Mol Cancer Ther 2008; 7: 7: 2070-2079.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">McCarroll J.A., Gan P.P., Erlich R.B. et al. TUBB3//3III-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer. Cancer Res 2015; 75: 2: 415-425.</mixed-citation><mixed-citation xml:lang="en">McCarroll J.A., Gan P.P., Erlich R.B. et al. TUBB3//3III-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer. Cancer Res 2015; 75: 2: 415-425.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Jordan A., Hadfield J.A., Lawrence N.J. et al. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998; 18: 4: 259-296.</mixed-citation><mixed-citation xml:lang="en">Jordan A., Hadfield J.A., Lawrence N.J. et al. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998; 18: 4: 259-296.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Karki R., Mariani M., Andreoli M. et al. βIII-Tubulin: biomarker of taxane resistance or drug target? Expert Opin Ther Targets 2013; 17: 4: 461-472.</mixed-citation><mixed-citation xml:lang="en">Karki R., Mariani M., Andreoli M. et al. βIII-Tubulin: biomarker of taxane resistance or drug target? Expert Opin Ther Targets 2013; 17: 4: 461-472.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Freedman H., Huzil J.T., Luchko T. et al. Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity. J Chem Inf Model 2009; 49: 2: 424-436.</mixed-citation><mixed-citation xml:lang="en">Freedman H., Huzil J.T., Luchko T. et al. Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity. J Chem Inf Model 2009; 49: 2: 424-436.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Andreoli M., Persico M., Kumar A. et al. Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells. J Med Chem 2014; 57: 19: 7916-7932.</mixed-citation><mixed-citation xml:lang="en">Andreoli M., Persico M., Kumar A. et al. Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells. J Med Chem 2014; 57: 19: 7916-7932.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Raspaglio G., Filippetti F., Prislei S. et al. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene 2008; 409: 1-2: 100-108.</mixed-citation><mixed-citation xml:lang="en">Raspaglio G., Filippetti F., Prislei S. et al. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene 2008; 409: 1-2: 100-108.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Raspaglio G., De Maria I., Filippetti F. et al. HuR regulates beta-tubulin isotype expression in ovarian cancer. Cancer Res 2010; 70: 14: 5891-5900.</mixed-citation><mixed-citation xml:lang="en">Raspaglio G., De Maria I., Filippetti F. et al. HuR regulates beta-tubulin isotype expression in ovarian cancer. Cancer Res 2010; 70: 14: 5891-5900.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Mozzetti S., Martinelli E., Raspaglio G. et al. Gli family transcription factors are drivers of patupilone resistance in ovarian cancer. Biochem Pharmacol 2012; 84: 11: 1409-1418.</mixed-citation><mixed-citation xml:lang="en">Mozzetti S., Martinelli E., Raspaglio G. et al. Gli family transcription factors are drivers of patupilone resistance in ovarian cancer. Biochem Pharmacol 2012; 84: 11: 1409-1418.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Saussede-Aim J., Matera E.L., Ferlini C. et al. Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-recep-tor dependent pathway. Cell Motil Cytoskeleton 2009; 66: 7: 378-388.</mixed-citation><mixed-citation xml:lang="en">Saussede-Aim J., Matera E.L., Ferlini C. et al. Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-recep-tor dependent pathway. Cell Motil Cytoskeleton 2009; 66: 7: 378-388.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">De Gendt K., Denolet E., Willems A. et al. Expression of Tubb3, a beta-tubulin isotype, is regulated by androgens in mouse and rat Sertoli cells. Biol Reprod 2011; 85: 5: 934-945.</mixed-citation><mixed-citation xml:lang="en">De Gendt K., Denolet E., Willems A. et al. Expression of Tubb3, a beta-tubulin isotype, is regulated by androgens in mouse and rat Sertoli cells. Biol Reprod 2011; 85: 5: 934-945.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Mariani M., Zannoni G.F., Sioletic S. et al. Gender influences the class III and V /З-tubulin ability to predict poor outcome in colorectal cancer. Clin Cancer Res 2012; 18: 10: 2964-2975.</mixed-citation><mixed-citation xml:lang="en">Mariani M., Zannoni G.F., Sioletic S. et al. Gender influences the class III and V /З-tubulin ability to predict poor outcome in colorectal cancer. Clin Cancer Res 2012; 18: 10: 2964-2975.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Terry S., Ploussard G., Allory Y. et al. Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer 2009; 101: 6: 951-956.</mixed-citation><mixed-citation xml:lang="en">Terry S., Ploussard G., Allory Y. et al. Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer 2009; 101: 6: 951-956.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Shibazaki M., Maesawa C., Akasaka K. et al. Transcriptional and post-transcriptional regulation of ßIII-tubulin protein expression in relation with cell cycle-dependent regulation of tumor cells Oncol 2012; 40: 3: 695-702.</mixed-citation><mixed-citation xml:lang="en">Shibazaki M., Maesawa C., Akasaka K. et al. Transcriptional and post-transcriptional regulation of ßIII-tubulin protein expression in relation with cell cycle-dependent regulation of tumor cells Oncol 2012; 40: 3: 695-702.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Mariani M., Karki R., Spennato M. et al. Class III /в-tubulin in normal and cancer tissues Gene 2015; 563: 2: 109-114.</mixed-citation><mixed-citation xml:lang="en">Mariani M., Karki R., Spennato M. et al. Class III /в-tubulin in normal and cancer tissues Gene 2015; 563: 2: 109-114.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Tischfield M.A., Baris H.N., Wu C. et al. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell 2010; 140: 1: 74-87.</mixed-citation><mixed-citation xml:lang="en">Tischfield M.A., Baris H.N., Wu C. et al. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell 2010; 140: 1: 74-87.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Katsetos C.D., Drâber P. Tubulins as therapeutic targets in cancer: from bench to bedside. Curr Pharm Des 2012; 18: 19: 2778-2792.</mixed-citation><mixed-citation xml:lang="en">Katsetos C.D., Drâber P. Tubulins as therapeutic targets in cancer: from bench to bedside. Curr Pharm Des 2012; 18: 19: 2778-2792.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis S.A., Cowan N.J. Complex regulation and functional versatility of mammalian alpha- and beta-tubulin isotypes during the differentiation of testis and muscle cells. J Cell Biol 1988; 106: 6: 2023-2033.</mixed-citation><mixed-citation xml:lang="en">Lewis S.A., Cowan N.J. Complex regulation and functional versatility of mammalian alpha- and beta-tubulin isotypes during the differentiation of testis and muscle cells. J Cell Biol 1988; 106: 6: 2023-2033.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Peknicova J., Kubatova A., Sulimenko V. et al. Differential subcellular distribution of tubulin epitopes in boar spermatozoa: recognition of class III-tubulin epitope in sperm tail. Biol Reprod 2001; 65: 672-679.</mixed-citation><mixed-citation xml:lang="en">Peknicova J., Kubatova A., Sulimenko V. et al. Differential subcellular distribution of tubulin epitopes in boar spermatozoa: recognition of class III-tubulin epitope in sperm tail. Biol Reprod 2001; 65: 672-679.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Locher H., Frijns J.H., Huisman M.A., de Sousa Lopes S.M. TUBB3: Neuronal Marker or Melanocyte Mimic? Cell Transplant 2014; 23: 11: 1471-1473.</mixed-citation><mixed-citation xml:lang="en">Locher H., Frijns J.H., Huisman M.A., de Sousa Lopes S.M. TUBB3: Neuronal Marker or Melanocyte Mimic? Cell Transplant 2014; 23: 11: 1471-1473.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Yu H., Fang D., Kumar S.M. et al. Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol 2006; 168: 6: 1879-1888.</mixed-citation><mixed-citation xml:lang="en">Yu H., Fang D., Kumar S.M. et al. Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol 2006; 168: 6: 1879-1888.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Katsetos C.D., Del Valle L., Geddes J.F. et al. Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status. J Neuropathol Exp Neurol 2002; 61: 4: 307-320.</mixed-citation><mixed-citation xml:lang="en">Katsetos C.D., Del Valle L., Geddes J.F. et al. Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status. J Neuropathol Exp Neurol 2002; 61: 4: 307-320.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Katsetos C.D., Del Valle L., Legido A. et al. On the neuronal/neuroblastic nature of medulloblastomas: a tribute to Pio del Rio Hortega and Moises Polak. Acta Neuropathol. 2003; 105: 1: 1-13.</mixed-citation><mixed-citation xml:lang="en">Katsetos C.D., Del Valle L., Legido A. et al. On the neuronal/neuroblastic nature of medulloblastomas: a tribute to Pio del Rio Hortega and Moises Polak. Acta Neuropathol. 2003; 105: 1: 1-13.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Packer R.J., Sutton L.N., Rorke L.B. et al. Prognostic importance of cellular differentiation in medulloblastoma of childhood. J Neurosurg 1984; 61: 2: 296-301.</mixed-citation><mixed-citation xml:lang="en">Packer R.J., Sutton L.N., Rorke L.B. et al. Prognostic importance of cellular differentiation in medulloblastoma of childhood. J Neurosurg 1984; 61: 2: 296-301.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Ikota H., Kinjo S., Yokoo H. et al. Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol 2006; 111: 5: 475-482.</mixed-citation><mixed-citation xml:lang="en">Ikota H., Kinjo S., Yokoo H. et al. Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol 2006; 111: 5: 475-482.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Katsetos C.D., Del Valle L., Geddes J.F. et al. Aberrant localization of the neuronal class III beta-tubulin in astrocytomas. Arch Pathol Lab Med 2001; 125: 5: 613-624.</mixed-citation><mixed-citation xml:lang="en">Katsetos C.D., Del Valle L., Geddes J.F. et al. Aberrant localization of the neuronal class III beta-tubulin in astrocytomas. Arch Pathol Lab Med 2001; 125: 5: 613-624.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Katsetos C.D., Draber P., Kavallaris M. Targeting /βIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics. Anticancer Agents Med Chem 2011; 11: 8: 719-728.</mixed-citation><mixed-citation xml:lang="en">Katsetos C.D., Draber P., Kavallaris M. Targeting /βIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics. Anticancer Agents Med Chem 2011; 11: 8: 719-728.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Jirâsek T., Pisarikova E., Viklicky V. et al. Expression of class III beta-tubulin in malignant epithelial tumours: an immunohistochemical study using TU-20 and TuJ-1 antibodies. Folia Histochem Cytobiol 2007; 45: 1: 41-45.</mixed-citation><mixed-citation xml:lang="en">Jirâsek T., Pisarikova E., Viklicky V. et al. Expression of class III beta-tubulin in malignant epithelial tumours: an immunohistochemical study using TU-20 and TuJ-1 antibodies. Folia Histochem Cytobiol 2007; 45: 1: 41-45.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Kavallaris M., Kuo D.Y., Burkhart C.A. et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100: 5: 1282-1293.</mixed-citation><mixed-citation xml:lang="en">Kavallaris M., Kuo D.Y., Burkhart C.A. et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100: 5: 1282-1293.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Mozzetti S., Ferlini C., Concolino P. et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005; 11: 1: 298-305.</mixed-citation><mixed-citation xml:lang="en">Mozzetti S., Ferlini C., Concolino P. et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005; 11: 1: 298-305.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Ferrandina G., Zannoni G.F., Martinelli E. et al. Class III -Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients. Clin Cancer Res 2006; 12: 9: 2774-2779.</mixed-citation><mixed-citation xml:lang="en">Ferrandina G., Zannoni G.F., Martinelli E. et al. Class III -Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients. Clin Cancer Res 2006; 12: 9: 2774-2779.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Su D., Smith S.M., Preti M. et al. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009; 115: 11: 2453-2463.</mixed-citation><mixed-citation xml:lang="en">Su D., Smith S.M., Preti M. et al. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009; 115: 11: 2453-2463.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Umezu T., Shibata K., Kajiyama H. et al. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int J Gynecol Pathol 2008; 27: 2: 207-212.</mixed-citation><mixed-citation xml:lang="en">Umezu T., Shibata K., Kajiyama H. et al. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int J Gynecol Pathol 2008; 27: 2: 207-212.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Aoki D., Oda Y., Hattori S. et al. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res 2009; 15: 4: 1473-1480.</mixed-citation><mixed-citation xml:lang="en">Aoki D., Oda Y., Hattori S. et al. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res 2009; 15: 4: 1473-1480.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Jakobsen J.N., Santoni-Rugiu E., Sorensen J.B. Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients. Cancer Chemother Pharmacol 2014; 73: 1: 43-51.</mixed-citation><mixed-citation xml:lang="en">Jakobsen J.N., Santoni-Rugiu E., Sorensen J.B. Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients. Cancer Chemother Pharmacol 2014; 73: 1: 43-51.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Jakobsen J.N., Santoni-Rugiu E. S.J.B. Use of TUBßIII for patient stratification and prognosis in lung cancer. Lung Cancer Manag 2015; 4: 2: 97-110.</mixed-citation><mixed-citation xml:lang="en">Jakobsen J.N., Santoni-Rugiu E. S.J.B. Use of TUBßIII for patient stratification and prognosis in lung cancer. Lung Cancer Manag 2015; 4: 2: 97-110.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Lebok P., Öztürk M., Heilenkötter U. et al. High levels of class III ß-tubulin expression are associated with aggressive tumor features in breast cancer. Oncol Lett 2016; 11: 3: 1987-1994.</mixed-citation><mixed-citation xml:lang="en">Lebok P., Öztürk M., Heilenkötter U. et al. High levels of class III ß-tubulin expression are associated with aggressive tumor features in breast cancer. Oncol Lett 2016; 11: 3: 1987-1994.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Kanojia D., Morshed R.A., Zhang L. et al. III-Tubulin Regulates Breast Cancer Metastases to the Brain. Mol Cancer Ther 2015; 14: 5: 1152-1161.</mixed-citation><mixed-citation xml:lang="en">Kanojia D., Morshed R.A., Zhang L. et al. III-Tubulin Regulates Breast Cancer Metastases to the Brain. Mol Cancer Ther 2015; 14: 5: 1152-1161.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Urano N., Fujiwara Y., Doki Y. et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 2006; 28: 2: 375-381.</mixed-citation><mixed-citation xml:lang="en">Urano N., Fujiwara Y., Doki Y. et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 2006; 28: 2: 375-381.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Gao J., Lu M., Yu J.W. et al. Thymidine Phosphorylase/ß-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer. 2011; 11: 1: 177.</mixed-citation><mixed-citation xml:lang="en">Gao J., Lu M., Yu J.W. et al. Thymidine Phosphorylase/ß-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer. 2011; 11: 1: 177.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Jirâsek T., Cipro S., Musilovâ A. et al. Expression of class III beta-tubu-lin in colorectal carcinomas: an immunohistochemical study using TU-20 &amp; TuJ-1 antibody. Indian J Med Res 2009; 129: 1: 89-94.</mixed-citation><mixed-citation xml:lang="en">Jirâsek T., Cipro S., Musilovâ A. et al. Expression of class III beta-tubu-lin in colorectal carcinomas: an immunohistochemical study using TU-20 &amp; TuJ-1 antibody. Indian J Med Res 2009; 129: 1: 89-94.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Sun H., Shi L., He X., Zheng S. Expressions of TUBB3 and gamma-synuclein in colorectal adenocarcinoma and their clinical significance. Zhonghua Yi Xue Za Zhi 2015; 95: 1242-1244.</mixed-citation><mixed-citation xml:lang="en">Sun H., Shi L., He X., Zheng S. Expressions of TUBB3 and gamma-synuclein in colorectal adenocarcinoma and their clinical significance. Zhonghua Yi Xue Za Zhi 2015; 95: 1242-1244.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Портянко А.С. Ремоделирование цитоскелета в патогенезе и прогрессии аденокарциномы и хронических воспалительных заболеваний толстой кишки: дис.. д-ра. биол. наук: 14.03.02 Минск 2016: 43.</mixed-citation><mixed-citation xml:lang="en">Портянко А.С. Ремоделирование цитоскелета в патогенезе и прогрессии аденокарциномы и хронических воспалительных заболеваний толстой кишки: дис.. д-ра. биол. наук: 14.03.02 Минск 2016: 43.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Egevad L., Valdman A., Wiklund N.P. et al. Beta-tubulin III expression in prostate cancer Scand J Urol Nephrol 2010; 44: 6: 371-377.</mixed-citation><mixed-citation xml:lang="en">Egevad L., Valdman A., Wiklund N.P. et al. Beta-tubulin III expression in prostate cancer Scand J Urol Nephrol 2010; 44: 6: 371-377.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Ploussard G., Terry S., Maillé P. et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res 2010; 70: 22: 9253-9264.</mixed-citation><mixed-citation xml:lang="en">Ploussard G., Terry S., Maillé P. et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res 2010; 70: 22: 9253-9264.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Hinsch A., Chaker A., Burdelski C. et al. /βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer. Hum Pathol 2017; 61: 210-220.</mixed-citation><mixed-citation xml:lang="en">Hinsch A., Chaker A., Burdelski C. et al. /βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer. Hum Pathol 2017; 61: 210-220.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Quaas A., Rahvar A.H., Burdelski C. et al. /βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma World J Urol 2015; 33: 10: 1561-1569.</mixed-citation><mixed-citation xml:lang="en">Quaas A., Rahvar A.H., Burdelski C. et al. /βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma World J Urol 2015; 33: 10: 1561-1569.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Ferrandina G., Martinelli E., Zannoni G.F. et al. Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome. Gynecol Oncol 2007; 104: 2: 326-330.</mixed-citation><mixed-citation xml:lang="en">Ferrandina G., Martinelli E., Zannoni G.F. et al. Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome. Gynecol Oncol 2007; 104: 2: 326-330.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Koh Y., Kim T.M., Jeon Y.K. et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol 2009; 20: 8: 1414-1419.</mixed-citation><mixed-citation xml:lang="en">Koh Y., Kim T.M., Jeon Y.K. et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol 2009; 20: 8: 1414-1419.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Kaira K., Serizawa M., Koh Y. et al. Expression of Excision Repair Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and ßIII-Tubulin in Thymic Epithelial Tumors. J Thorac Oncol 2011; 6: 3: 606-613.</mixed-citation><mixed-citation xml:lang="en">Kaira K., Serizawa M., Koh Y. et al. Expression of Excision Repair Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and ßIII-Tubulin in Thymic Epithelial Tumors. J Thorac Oncol 2011; 6: 3: 606-613.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Akasaka K., Maesawa C., Shibazaki M. et al. Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells. J Invest Dermatol 2009; 129: 6: 1516-1526.</mixed-citation><mixed-citation xml:lang="en">Akasaka K., Maesawa C., Shibazaki M. et al. Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells. J Invest Dermatol 2009; 129: 6: 1516-1526.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Miyamoto A., Akasaka K., Oikawa H. et al. Immunohistochemical study of HER2 and TUBB3 proteins in extramammary Paget disease. Am J Dermatopathol 2010; 32: 6: 578-585.</mixed-citation><mixed-citation xml:lang="en">Miyamoto A., Akasaka K., Oikawa H. et al. Immunohistochemical study of HER2 and TUBB3 proteins in extramammary Paget disease. Am J Dermatopathol 2010; 32: 6: 578-585.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Ishida M., Kushima R., Okabe H. Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin. Oncol Rep 2009; 22: 4: 733-737.</mixed-citation><mixed-citation xml:lang="en">Ishida M., Kushima R., Okabe H. Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin. Oncol Rep 2009; 22: 4: 733-737.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Powell S., Kaizer A., Koopmeiners J.S. et al. High expression of class IIIß tubulin in small cell lung carcinoma. Oncol Lett 2013; 7: 2: 405-410.</mixed-citation><mixed-citation xml:lang="en">Powell S., Kaizer A., Koopmeiners J.S. et al. High expression of class IIIß tubulin in small cell lung carcinoma. Oncol Lett 2013; 7: 2: 405-410.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Ting S, Mairinger F.D, Hager T. et al. ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural. mesothelioma. Clin Lung Cancer 2013; 14: 558-567.</mixed-citation><mixed-citation xml:lang="en">Ting S, Mairinger F.D, Hager T. et al. ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural. mesothelioma. Clin Lung Cancer 2013; 14: 558-567.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Yoon S.O. et al. Class III beta-tubulin shows unique expression patterns in a variety of neoplastic and non-neoplastic lymphoproliferative disorders. Am. J. Surg. Pathol. 2010; 34: 5: 645-655.</mixed-citation><mixed-citation xml:lang="en">Yoon S.O. et al. Class III beta-tubulin shows unique expression patterns in a variety of neoplastic and non-neoplastic lymphoproliferative disorders. Am. J. Surg. Pathol. 2010; 34: 5: 645-655.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Okuda K., Sasaki H., Dumontet C. et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 2008; 62: 1: 105-112.</mixed-citation><mixed-citation xml:lang="en">Okuda K., Sasaki H., Dumontet C. et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 2008; 62: 1: 105-112.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Kang C.H., Jang B.G., Kim D.W. et al. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 2010; 68: 3: 478-483.</mixed-citation><mixed-citation xml:lang="en">Kang C.H., Jang B.G., Kim D.W. et al. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 2010; 68: 3: 478-483.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Azuma K., Sasada T., Kawahara A. et al. Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009; 64: 3: 326-333.</mixed-citation><mixed-citation xml:lang="en">Azuma K., Sasada T., Kawahara A. et al. Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009; 64: 3: 326-333.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Ikeda S., Takabe K., Suzuki K. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathol Int 2009; 59: 12: 863-867.</mixed-citation><mixed-citation xml:lang="en">Ikeda S., Takabe K., Suzuki K. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathol Int 2009; 59: 12: 863-867.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Q., Zhu X., Zhang L. et al. A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2014; 74: 4: 839-846.</mixed-citation><mixed-citation xml:lang="en">Zhang Q., Zhu X., Zhang L. et al. A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2014; 74: 4: 839-846.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Chen X., Wu J., Lu H. et al. Measuring ß-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer. Cancer Sci 2012; 103: 2: 262-268.</mixed-citation><mixed-citation xml:lang="en">Chen X., Wu J., Lu H. et al. Measuring ß-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer. Cancer Sci 2012; 103: 2: 262-268.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Leandro-Garcfa L.J., Leskelä S., Landa I. et al. Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken) 2010; 67: 4: 214-223.</mixed-citation><mixed-citation xml:lang="en">Leandro-Garcfa L.J., Leskelä S., Landa I. et al. Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken) 2010; 67: 4: 214-223.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Ishida M., Kushima R., Okabe H. Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin. Oncol Rep 2009; 22: 4: 733-737.</mixed-citation><mixed-citation xml:lang="en">Ishida M., Kushima R., Okabe H. Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin. Oncol Rep 2009; 22: 4: 733-737.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Orfanidis K., Wäster P., Lundmark K. et al. Evaluation of tubulinß-3 as a novel senescence-associated gene in melanocytic malignant transformation. Pigment Cell Melanoma Res 2017; 30: 2: 243-254.</mixed-citation><mixed-citation xml:lang="en">Orfanidis K., Wäster P., Lundmark K. et al. Evaluation of tubulinß-3 as a novel senescence-associated gene in melanocytic malignant transformation. Pigment Cell Melanoma Res 2017; 30: 2: 243-254.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Мамичев И.А., Богуш Т.А., Дудко Е. А. и др. Иммунофлуоресцентный анализ экспрессии бета-III тубулина в опухолевой и окружающей нормальной ткани пациентов с немелкоклеточным раком легкого. Росс биотер журнал. - 2016. - Т. 15. - № 2. - С. 16-18.</mixed-citation><mixed-citation xml:lang="en">Мамичев И.А., Богуш Т.А., Дудко Е. А. и др. Иммунофлуоресцентный анализ экспрессии бета-III тубулина в опухолевой и окружающей нормальной ткани пациентов с немелкоклеточным раком легкого. Росс биотер журнал. - 2016. - Т. 15. - № 2. - С. 16-18.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
